Suven gets three product patents in Australia, South Korea, China

The new patents expand Suven's drug discovery portfolio into several new therapeutic areas

Hyderabad-based biopharmaceutical company, Suven Life Sciences Limited, has secured a product patent each from Australia, South Korea and China corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases. These patents are valid through 2029, 2029 and 2030 respectively.

The new product patents expand Suven's drug discovery portfolio into several new therapeutic areas like major depressive disorder (MDD), obesity and pain through neuronal nicotinic receptor modulators, the company said in a filing to the BSE on Monday.

The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for MDD, it added.

With these new patents, Suven now has 17 granted product patents from Australia, 13 from South Korea and 13 from China.

Suven Life's scrip is currently trading at Rs 86.50 on the BSE, up 3.78%, over the previous close of Rs 83.35.